ofloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibacterials, nalidixic acid derivatives	1981	82419-36-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: gailuoxian ofloxacine oxaldin prifloxcin prifloxin ofloxacin ofloxacin hydrochloride ofloxacin HCl	A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. Molecular weight: 361.37 Formula: C18H20FN3O4 CLOGP: -0.26 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 73.32 ALOGS: -2.40 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

gailuoxian
ofloxacine
oxaldin
prifloxcin
prifloxin
ofloxacin
ofloxacin hydrochloride
ofloxacin HCl

A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Molecular weight: 361.37
Formula: C18H20FN3O4
CLOGP: -0.26
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 73.32
ALOGS: -2.40
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O
0.40	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	3.54 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	64 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	31.62 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.75 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 28, 1990	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endophthalmitis	106.47	15.71	32	7554	3560	63477876
Toxic anterior segment syndrome	94.55	15.71	25	7561	1746	63479690
Acute kidney injury	78.06	15.71	124	7462	263291	63218145
Hypopyon	72.69	15.71	17	7569	715	63480721
Corneal perforation	66.59	15.71	15	7571	533	63480903
Drug reaction with eosinophilia and systemic symptoms	65.19	15.71	44	7542	33792	63447644
Cholestasis	60.86	15.71	40	7546	29394	63452042
Eye pain	53.50	15.71	39	7547	33815	63447621
Rash maculo-papular	53.28	15.71	38	7548	31858	63449578
Eosinophilia	52.16	15.71	33	7553	22723	63458713
Corneal oedema	51.67	15.71	15	7571	1478	63479958
Drug resistance	47.00	15.71	31	7555	22902	63458534
Cataract	46.84	15.71	45	7541	57008	63424428
Corneal deposits	46.42	15.71	10	7576	288	63481148
Corneal erosion	46.25	15.71	10	7576	293	63481143
Corneal infiltrates	41.27	15.71	8	7578	134	63481302
Keratitis fungal	39.97	15.71	8	7578	159	63481277
Acute generalised exanthematous pustulosis	38.36	15.71	21	7565	11078	63470358
Agranulocytosis	37.56	15.71	28	7558	25106	63456330
Tendonitis	36.56	15.71	25	7561	19590	63461846
Tendon pain	36.28	15.71	14	7572	3312	63478124
Psychotic disorder due to a general medical condition	35.97	15.71	8	7578	268	63481168
Renal necrosis	34.00	15.71	6	7580	58	63481378
Toxic epidermal necrolysis	32.98	15.71	26	7560	25308	63456128
Visual acuity reduced	31.91	15.71	24	7562	21802	63459634
Retinal pigment epithelial tear	30.98	15.71	7	7579	252	63481184
Gingival ulceration	30.67	15.71	9	7577	921	63480515
Prothrombin time ratio decreased	30.66	15.71	8	7578	530	63480906
Toxic skin eruption	30.31	15.71	19	7567	12866	63468570
Encephalopathy	28.96	15.71	29	7557	38591	63442845
Ulcerative keratitis	28.11	15.71	11	7575	2699	63478737
Hepatic cytolysis	27.21	15.71	19	7567	15388	63466048
Vascular purpura	26.56	15.71	9	7577	1469	63479967
Drug hypersensitivity	26.12	15.71	89	7497	310598	63170838
Anuria	25.79	15.71	17	7569	12534	63468902
Periodontal disease	25.60	15.71	9	7577	1639	63479797
Eye irritation	25.31	15.71	21	7565	21950	63459486
Hepatocellular injury	25.15	15.71	23	7563	27358	63454078
Face oedema	24.72	15.71	20	7566	20192	63461244
International normalised ratio increased	24.55	15.71	29	7557	46396	63435040
Drug interaction	24.16	15.71	71	7515	229060	63252376
Tendon rupture	24.16	15.71	14	7572	8225	63473211
Eye infection	23.87	15.71	16	7570	12129	63469307
Confusional state	23.75	15.71	72	7514	236308	63245128
Necrosis	23.55	15.71	12	7574	5475	63475961
Hepatitis	22.96	15.71	26	7560	39762	63441674
Tendon disorder	22.84	15.71	12	7574	5831	63475605
Hyperthermia	22.79	15.71	14	7572	9142	63472294
Periodontitis	22.72	15.71	10	7576	3293	63478143
Renal failure	22.66	15.71	46	7540	117606	63363830
Visual impairment	22.53	15.71	38	7548	84408	63397028
Intraocular pressure increased	22.39	15.71	12	7574	6066	63475370
Thrombocytopenia	22.20	15.71	53	7533	151104	63330332
Sinonasal papilloma	22.11	15.71	4	7582	45	63481391
Keratolysis exfoliativa acquired	22.02	15.71	3	7583	3	63481433
Reversible cerebral vasoconstriction syndrome	21.42	15.71	9	7577	2649	63478787
Anterior segment ischaemia	21.37	15.71	4	7582	55	63481381
Anterior chamber cell	21.22	15.71	6	7580	538	63480898
Dermatitis bullous	21.16	15.71	13	7573	8495	63472941
Corneal disorder	21.09	15.71	8	7578	1806	63479630
Type I hypersensitivity	20.54	15.71	9	7577	2933	63478503
Pyelonephritis	20.50	15.71	17	7569	17761	63463675
Hepatitis acute	20.33	15.71	13	7573	9107	63472329
Extensor plantar response	19.76	15.71	7	7579	1304	63480132
Infusion related reaction	19.54	15.71	3	7583	245518	63235918
Non-cardiogenic pulmonary oedema	19.47	15.71	6	7580	725	63480711
Shock haemorrhagic	19.36	15.71	13	7573	9882	63471554
Pupillary block	19.27	15.71	3	7583	12	63481424
Keratitis	19.24	15.71	9	7577	3413	63478023
Corneal epithelium defect	18.93	15.71	5	7581	347	63481089
Corneal scar	18.78	15.71	4	7582	109	63481327
Mucosal erosion	18.77	15.71	7	7579	1509	63479927
Cutaneous vasculitis	18.29	15.71	10	7576	5259	63476177
Vitritis	17.67	15.71	6	7580	986	63480450
Ocular hyperaemia	17.25	15.71	18	7568	25126	63456310
Factor V inhibition	17.02	15.71	4	7582	172	63481264
Joint swelling	16.98	15.71	9	7577	327657	63153779
Aortic dissection	16.82	15.71	7	7579	2011	63479425
Central nervous system immune reconstitution inflammatory response	16.82	15.71	3	7583	31	63481405
Metamorphopsia	16.73	15.71	6	7580	1157	63480279
Contraindicated product administered	16.56	15.71	3	7583	217645	63263791
Photophobia	16.56	15.71	15	7571	17620	63463816
Pathogen resistance	16.48	15.71	10	7576	6388	63475048
Clostridium difficile colitis	16.44	15.71	16	7570	20553	63460883
Cardioactive drug level increased	16.24	15.71	7	7579	2193	63479243
Hepatitis cholestatic	15.82	15.71	10	7576	6868	63474568

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	156.51	15.95	93	7197	32919	34916722
Type 2 lepra reaction	79.66	15.95	16	7274	179	34949462
Tendonitis	77.71	15.95	38	7252	9102	34940539
Cholestasis	73.97	15.95	54	7236	26894	34922747
Hepatocellular injury	71.35	15.95	49	7241	22162	34927479
Rash maculo-papular	62.64	15.95	50	7240	28401	34921240
Agranulocytosis	59.25	15.95	45	7245	23776	34925865
Toxic epidermal necrolysis	58.54	15.95	43	7247	21603	34928038
Endophthalmitis	57.07	15.95	23	7267	3485	34946156
Eosinophilia	55.42	15.95	45	7245	26177	34923464
Corneal oedema	53.00	15.95	17	7273	1334	34948307
Ulcerative keratitis	52.77	15.95	18	7272	1711	34947930
Acute kidney injury	48.16	15.95	156	7134	304832	34644809
Keratitis fungal	47.71	15.95	10	7280	140	34949501
Tendon pain	46.54	15.95	19	7271	2976	34946665
Eye pain	46.32	15.95	31	7259	13431	34936210
Hyperacusis	42.58	15.95	13	7277	867	34948774
Tendon rupture	41.87	15.95	23	7267	6989	34942652
Corneal deposits	38.40	15.95	9	7281	215	34949426
Visual acuity reduced	36.85	15.95	29	7261	16120	34933521
Laryngeal haematoma	35.07	15.95	8	7282	169	34949472
Motion sickness	33.98	15.95	8	7282	195	34949446
Chronic fatigue syndrome	33.89	15.95	9	7281	362	34949279
Skin hyperpigmentation	32.09	15.95	15	7275	3249	34946392
Tendon disorder	30.72	15.95	14	7276	2861	34946780
Corneal opacity	29.82	15.95	9	7281	577	34949064
Distal intestinal obstruction syndrome	29.52	15.95	8	7282	348	34949293
Purpura	29.03	15.95	21	7269	10290	34939351
Corneal epithelium defect	29.02	15.95	8	7282	371	34949270
Vascular purpura	26.67	15.95	11	7279	1767	34947874
Retinal pigment epithelial tear	26.49	15.95	7	7283	276	34949365
Corneal thinning	25.69	15.95	6	7284	141	34949500
Upper airway obstruction	24.58	15.95	8	7282	657	34948984
Anterior chamber cell	24.54	15.95	7	7283	368	34949273
Haemolytic anaemia	24.30	15.95	19	7271	10460	34939181
Hyperthermia	24.14	15.95	19	7271	10558	34939083
Intraocular pressure increased	22.46	15.95	14	7276	5369	34944272
Aqueous humour leakage	22.43	15.95	3	7287	0	34949641
Tendon discomfort	22.16	15.95	6	7284	260	34949381
Corneal disorder	21.92	15.95	8	7282	926	34948715
Eye inflammation	21.21	15.95	10	7280	2208	34947433
Rash morbilliform	20.87	15.95	11	7279	3076	34946565
Muscle rupture	20.87	15.95	10	7280	2288	34947353
Toxic skin eruption	20.85	15.95	18	7272	11367	34938274
Dysaesthesia	20.84	15.95	10	7280	2295	34947346
Hepatic cytolysis	20.83	15.95	20	7270	14476	34935165
Red blood cell vacuolisation	20.35	15.95	3	7287	3	34949638
Toxic anterior segment syndrome	20.18	15.95	8	7282	1161	34948480
Cataract	20.06	15.95	26	7264	26160	34923481
Corneal infiltrates	20.05	15.95	5	7285	156	34949485
Fibrin	19.89	15.95	3	7287	4	34949637
Hypopyon	19.80	15.95	6	7284	390	34949251
Muscle contractions involuntary	19.71	15.95	9	7281	1847	34947794
Haematoma	18.96	15.95	25	7265	25580	34924061
Corneal perforation	18.88	15.95	5	7285	199	34949442
Pudendal canal syndrome	18.82	15.95	3	7287	7	34949634
Drug resistance	18.71	15.95	25	7265	25902	34923739
Sideroblastic anaemia	17.70	15.95	5	7285	254	34949387
Vitreous haemorrhage	17.61	15.95	9	7281	2364	34947277
Tuberculoma of central nervous system	17.60	15.95	5	7285	259	34949382
Orchitis	17.52	15.95	8	7282	1641	34948000
Intra-abdominal haemorrhage	17.50	15.95	9	7281	2395	34947246
Prostatitis	17.32	15.95	12	7278	5495	34944146
Atrophy	17.19	15.95	7	7283	1088	34948553
Thrombocytopenia	16.99	15.95	71	7219	156176	34793465
Staphylococcal infection	16.96	15.95	27	7263	32733	34916908
Dermatitis exfoliative generalised	16.38	15.95	10	7280	3697	34945944
Immune reconstitution inflammatory syndrome	16.35	15.95	14	7276	8745	34940896
Oral candidiasis	16.08	15.95	16	7274	12094	34937547

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	208.44	13.83	132	13422	64112	79666722
Endophthalmitis	150.05	13.83	52	13502	6376	79724458
Cholestasis	125.46	13.83	89	13465	52020	79678814
Acute kidney injury	115.73	13.83	265	13289	519139	79211695
Rash maculo-papular	112.93	13.83	86	13468	55992	79674842
Toxic anterior segment syndrome	107.82	13.83	33	13521	2731	79728103
Corneal oedema	101.01	13.83	31	13523	2589	79728245
Eosinophilia	98.99	13.83	73	13481	45272	79685562
Tendonitis	97.88	13.83	57	13497	23773	79707061
Type 2 lepra reaction	92.59	13.83	18	13536	210	79730624
Hepatocellular injury	87.13	13.83	69	13485	47524	79683310
Toxic epidermal necrolysis	86.74	13.83	67	13487	44514	79686320
Agranulocytosis	86.14	13.83	67	13487	44963	79685871
Corneal perforation	80.91	13.83	20	13534	743	79730091
Hypopyon	77.57	13.83	21	13533	1121	79729713
Corneal deposits	73.24	13.83	17	13537	481	79730353
Keratitis fungal	69.17	13.83	15	13539	309	79730525
Tendon pain	67.38	13.83	28	13526	5630	79725204
Ulcerative keratitis	60.50	13.83	23	13531	3666	79727168
Eye pain	59.35	13.83	50	13504	37528	79693306
Retinal pigment epithelial tear	58.24	13.83	14	13540	462	79730372
Tendon rupture	55.13	13.83	31	13523	12095	79718739
Drug resistance	54.32	13.83	50	13504	42163	79688671
Vascular purpura	53.28	13.83	20	13534	3078	79727756
Corneal infiltrates	53.20	13.83	12	13542	298	79730536
Visual acuity reduced	48.16	13.83	40	13514	29429	79701405
Toxic skin eruption	46.64	13.83	35	13519	22258	79708576
Hyperthermia	46.15	13.83	32	13522	18005	79712829
Hepatic cytolysis	44.68	13.83	37	13517	27114	79703720
Prothrombin time ratio decreased	44.56	13.83	13	13541	912	79729922
Anterior chamber cell	44.23	13.83	13	13541	936	79729898
Corneal opacity	43.30	13.83	13	13541	1007	79729827
Tendon disorder	42.84	13.83	22	13532	7164	79723670
Thrombocytopenia	38.90	13.83	116	13438	265143	79465691
Corneal epithelium defect	38.63	13.83	11	13543	708	79730126
Acute generalised exanthematous pustulosis	38.13	13.83	28	13526	17226	79713608
Psychotic disorder due to a general medical condition	37.89	13.83	9	13545	282	79730552
International normalised ratio increased	37.28	13.83	58	13496	84663	79646171
Laryngeal haematoma	36.52	13.83	8	13546	173	79730661
Hepatitis	36.22	13.83	46	13508	55681	79675153
Cataract	35.30	13.83	48	13506	62072	79668762
Haemolytic anaemia	35.12	13.83	27	13527	17793	79713041
Intraocular pressure increased	35.11	13.83	21	13533	9184	79721650
Hyperacusis	33.38	13.83	13	13541	2210	79728624
Keratolysis exfoliativa acquired	32.59	13.83	5	13549	11	79730823
Skin hyperpigmentation	31.39	13.83	18	13536	7285	79723549
Corneal erosion	30.62	13.83	8	13546	372	79730462
Corneal disorder	29.53	13.83	12	13542	2279	79728555
Encephalopathy	29.45	13.83	46	13508	67351	79663483
Infusion related reaction	28.48	13.83	3	13551	230234	79500600
Keratitis	28.01	13.83	14	13540	4308	79726526
Chronic fatigue syndrome	28.00	13.83	10	13544	1337	79729497
Renal necrosis	27.94	13.83	7	13547	275	79730559
Corneal scar	27.32	13.83	7	13547	301	79730533
Purpura	26.82	13.83	24	13530	19503	79711331
Ocular hyperaemia	26.23	13.83	28	13526	28178	79702656
Dizziness	25.75	13.83	31	13523	526410	79204424
Eye irritation	25.63	13.83	24	13530	20657	79710177
Corneal graft rejection	25.59	13.83	5	13549	60	79730774
Corneal thinning	25.29	13.83	6	13548	187	79730647
Confusional state	25.26	13.83	114	13440	317883	79412951
Distal intestinal obstruction syndrome	24.87	13.83	8	13546	779	79730055
Periodontal disease	24.81	13.83	10	13544	1860	79728974
Cutaneous vasculitis	24.36	13.83	16	13538	8236	79722598
Renal failure	24.05	13.83	82	13472	200886	79529948
Fatigue	23.79	13.83	80	13474	929647	78801187
Motion sickness	23.60	13.83	8	13546	917	79729917
Gamma-glutamyltransferase increased	23.44	13.83	37	13517	54643	79676191
Rash morbilliform	23.38	13.83	14	13540	6136	79724698
Gingival ulceration	23.17	13.83	8	13546	969	79729865
Fibrin	23.09	13.83	4	13550	23	79730811
Eye inflammation	22.84	13.83	14	13540	6399	79724435
Vitritis	21.77	13.83	9	13545	1785	79729049
Weight increased	21.69	13.83	10	13544	277376	79453458
Visual impairment	21.46	13.83	48	13506	92083	79638751
Delusion of reference	21.29	13.83	5	13549	149	79730685
Vitreous haemorrhage	21.08	13.83	11	13543	3702	79727132
Sinonasal papilloma	20.79	13.83	4	13550	44	79730790
Dermatitis bullous	20.54	13.83	18	13536	14227	79716607
Hyperbilirubinaemia	20.47	13.83	23	13531	24495	79706339
Upper airway obstruction	20.21	13.83	8	13546	1420	79729414
Red blood cell vacuolisation	20.10	13.83	3	13551	5	79730829
Reversible cerebral vasoconstriction syndrome	20.10	13.83	10	13544	3047	79727787
Anterior segment ischaemia	19.97	13.83	4	13550	55	79730779
Mucosal erosion	19.56	13.83	9	13545	2309	79728525
Retinal oedema	19.44	13.83	7	13547	958	79729876
Haematoma	19.24	13.83	33	13521	52162	79678672
Hepatitis acute	19.19	13.83	18	13536	15524	79715310
Eye infection	19.10	13.83	16	13538	11904	79718930
Immune reconstitution inflammatory syndrome	18.98	13.83	17	13537	13824	79717010
Pudendal canal syndrome	18.88	13.83	3	13551	9	79730825
Vitreous floaters	18.86	13.83	13	13541	7243	79723591
Tuberculoma of central nervous system	18.68	13.83	6	13548	581	79730253
Toxicity to various agents	18.37	13.83	27	13527	421513	79309321
Dermatitis exfoliative	18.32	13.83	15	13539	10814	79720020
Sideroblastic anaemia	18.30	13.83	5	13549	276	79730558
Neuropathy peripheral	18.09	13.83	59	13495	141246	79589588
Conjunctivitis	17.94	13.83	22	13532	25693	79705141
Necrosis	17.87	13.83	14	13540	9479	79721355
Gastroenteritis staphylococcal	17.85	13.83	5	13549	303	79730531
Muscle atrophy	17.84	13.83	15	13539	11217	79719617
Peripheral swelling	17.79	13.83	12	13542	269605	79461229
Drug interaction	17.73	13.83	126	13428	415057	79315777
Ecchymosis	17.62	13.83	17	13537	15189	79715645
Orchitis	17.20	13.83	7	13547	1334	79729500
Aortic dissection	17.17	13.83	10	13544	4165	79726669
Conjunctival retraction	17.07	13.83	3	13551	19	79730815
Dermatitis exfoliative generalised	16.56	13.83	12	13542	7229	79723605
Dysaesthesia	16.44	13.83	11	13543	5837	79724997
Face oedema	16.37	13.83	22	13532	28114	79702720
Synovitis	16.21	13.83	3	13551	150731	79580103
Hepatosplenomegaly	16.07	13.83	11	13543	6058	79724776
Anterior chamber flare	15.87	13.83	4	13550	161	79730673
No adverse event	15.71	13.83	25	13529	37167	79693667
Persecutory delusion	15.67	13.83	10	13544	4899	79725935
Tendon discomfort	15.67	13.83	5	13549	474	79730360
Alopecia	15.66	13.83	10	13544	231345	79499489
Staphylococcal infection	15.44	13.83	32	13522	58263	79672571
Muscle contractions involuntary	15.44	13.83	9	13545	3756	79727078
Henoch-Schonlein purpura	15.30	13.83	8	13546	2702	79728132
Malnutrition	15.29	13.83	19	13535	22483	79708351
Swelling	15.18	13.83	9	13545	216702	79514132
Completed suicide	14.84	13.83	12	13542	245755	79485079
Pupillary block	14.67	13.83	3	13551	46	79730788
Prostatitis	14.52	13.83	9	13545	4193	79726641
Transaminases increased	14.41	13.83	29	13525	51714	79679120
Central nervous system immune reconstitution inflammatory response	14.16	13.83	3	13551	55	79730779
Atrophy	14.15	13.83	7	13547	2107	79728727
Drug abuse	14.12	13.83	5	13549	162686	79568148
Metamorphopsia	14.06	13.83	6	13548	1287	79729547
Vasculitis necrotising	14.03	13.83	6	13548	1294	79729540
Periodontitis	13.96	13.83	9	13545	4487	79726347
Dyspnoea	13.95	13.83	87	13467	856938	78873896
Glaucoma	13.93	13.83	17	13537	19744	79711090
Corneal abscess	13.92	13.83	3	13551	60	79730774
Intra-abdominal haemorrhage	13.88	13.83	9	13545	4531	79726303

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01MA01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones
ATC	J01RA09	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
ATC	S01AE01	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Fluoroquinolones
ATC	S02AA16	SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives
FDA CS	M0023650	Quinolones
CHEBI has role	CHEBI:35441	antiinfective agents
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50750	inhibitors of type II topoisomerase
CHEBI has role	CHEBI:53559	topoisomerase IV inhibitors
CHEBI has role	CHEBI:59517	DNA synthesis inhibitors
FDA EPC	N0000175937	Quinolone Antimicrobial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000892	Anti-Infective Agents, Urinary
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D065609	Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D059005	Topoisomerase II Inhibitors
MeSH PA	D059003	Topoisomerase Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Otitis externa	indication	3135009
Typhoid fever	indication	4834000	DOID:13258
Septicemia due to Escherichia coli	indication	9323009
Prostatitis	indication	9713002	DOID:14654
Infection due to Pseudomonas aeruginosa	indication	11218009
Gonorrhea	indication	15628003	DOID:7551
Enteric campylobacteriosis	indication	18081009
Infectious diarrheal disease	indication	19213003	DOID:13250
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Staphylococcal pneumonia	indication	22754005
Acute gonococcal urethritis	indication	29864006
Acute bacterial peritonitis	indication	31860008
Bronchitis	indication	32398004	DOID:6132
Postoperative infection	indication	33910007
Pneumonia due to Streptococcus	indication	34020007
Shigellosis	indication	36188001
Cystitis	indication	38822007	DOID:1679
Pneumonia due to Pseudomonas	indication	41381004
Gonorrhea of rectum	indication	42746002
Pyelonephritis	indication	45816000	DOID:11400
Pneumonia due to Mycoplasma pneumoniae	indication	46970008
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Acute gonococcal endometritis	indication	65295003	DOID:7527
Acute maxillary sinusitis	indication	68272006	DOID:2050
Urinary tract infectious disease	indication	68566005
Haemophilus influenzae pneumonia	indication	70036007
Infection due to Escherichia coli	indication	71057007
Rhinoscleroma	indication	72409005	DOID:11336
Abdominal abscess	indication	75100008
Acute bacterial sinusitis	indication	75498004
Nongonococcal urethritis	indication	84619001
Infective otitis externa	indication	86981007	DOID:9463
Chronic tubotympanic suppurative otitis media	indication	87665008	DOID:14435
Infection of bone	indication	111253001
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Bacterial conjunctivitis	indication	128350005	DOID:9700
Infection due to Enterobacteriaceae	indication	128945009
Urethritis due to Chlamydia trachomatis	indication	179101003
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Chlamydial pelvic inflammatory disease	indication	188463006
Acute Moraxella catarrhalis bronchitis	indication	195722003
Proteus pneumonia	indication	195888009
Malignant otitis externa due to Pseudomonas aeruginosa	indication	232230009
Acute bacterial bronchitis	indication	233598009
Pneumonia	indication	233604007	DOID:552
Pneumococcal pneumonia	indication	233607000
Chlamydial pneumonia	indication	233609002
Infective cystitis	indication	236620008
Chancroid	indication	266143009	DOID:13778
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infectious disorder of joint	indication	363162000
Infection due to Staphylococcus aureus	indication	406602003
Anthrax	indication	409498004	DOID:7427
Acute osteomyelitis	indication	409780002
Nosocomial pneumonia	indication	425464007
Acute exacerbation of chronic bronchitis	indication	425748003
Urinary tract infection caused by Klebsiella	indication	369001000119100
Pseudomonas Aeruginosa Urinary Tract Infection	indication
Enterobacter Pneumonia	indication
Mixed Gonococcal and Chlamydia Infection of the Urethra	indication
Complicated Bacteroides Peritonitis	indication
Pseudomonas Aeruginosa Cystitis	indication
Skin and Skin Structure Serratia Infection	indication
Complicated Bacterial Peritonitis	indication
Chlamydia Cervicitis	indication
Haemophilus Influenzae Chronic Bronchitis	indication
Complicated Skin and Skin Structure Proteus Infection	indication
Streptococcus Pneumoniae Bronchitis	indication
Moraxella Catarrhalis Chronic Bronchitis	indication
Chronic Staphylococcus epidermidis Prostatitis	indication
Pseudomonas Aeruginosa Osteomyelitis	indication
Haemophilus Parainfluenzae Pneumonia	indication
Enterobacter Osteomyelitis	indication
Providencia Urinary Tract Infection	indication
Nosocomial Pneumonia due to Serratia Marcescens	indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea	indication
Complicated Proteus UTI	indication
Chronic Bacterial Prostatitis	indication
Gram-Negative Aerobic Bacillary Pneumonia	indication
Proteus Prostatitis	indication
Staphylococcus Epidermidis Skin and Skin Structure Infection	indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection	indication
Serratia Joint Infection	indication
Skin and Skin Structure Morganella Morganii Infection	indication
Complicated Urinary Tract Infections	indication
Nosocomial Pneumonia due to Escherichia Coli	indication
Skin and Skin Structure Citrobacter Infection	indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection	indication
Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa	indication
Chronic Enterococcus faecalis Prostatitis	indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection	indication
Colorectal Surgery Infection Prevention	indication
Bacterial Corneal Ulcer Infection	indication
Legionella Pneumophila Pneumonia	indication
Complicated E. Coli Peritonitis	indication
Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus	indication
Mixed Gonococcal and Chlamydia Infection of the Cervix	indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection	indication
Serratia Urinary Tract Infection	indication
Diarrhea due to E. Coli	indication
Moraxella Catarrhalis Pneumonia	indication
E. Coli Pyelonephritis	indication
Serratia Osteomyelitis	indication
Staphylococcus Epidermidis Urinary Tract Infection	indication
E. Coli Cystitis	indication
Enterobacter Cystitis	indication
Chronic Escherichia coli Prostatitis	indication
Complicated UTI with Pseudomonas Aeruginosa	indication
Pseudomonas Aeruginosa Joint Infection	indication
Citrobacter Urinary Tract Infection	indication
Citrobacter Complicated UTI	indication
Skin and Skin Structure Proteus Infection	indication
Streptococcus Pneumoniae Chronic Bronchitis	indication
Staphylococcus Aureus Otitis Externa	indication
Klebsiella Nosocomial Pneumonia	indication
Enterococcus Complicated UTI	indication
Haemophilus Parainfluenzae Bronchitis	indication
Citrobacter Cystitis	indication
Enterococcus Urinary Tract Infection	indication
Haemophilus Influenzae Bronchitis	indication
Staphylococcus Saprophyticus Urinary Tract Infection	indication
Staphylococcus Aureus Bronchitis	indication
Morganella Morganii Urinary Tract Infection	indication
Staphylococcus Cystitis	indication
Complicated Klebsiella Peritonitis	indication
Nosocomial Pneumonia due to Streptococcus Pneumoniae	indication
Complicated Skin and Skin Structure Infection	indication
Nosocomial Pneumonia due to Klebsiella Pneumoniae	indication
EnterobacterJoint Infection	indication
Nosocomial Pneumonia due to Haemophilus Influenzae	indication
Skin and Skin Structure Providencia Infection	indication
Proteus Cystitis	indication
Vaginal Hysterectomy Infection Prevention	indication
Inhalational anthrax	off-label use	11389007
Traveler's diarrhea	off-label use	11840006
Acute tuberculosis	off-label use	25629007
Salmonella septicemia	off-label use	49786009
Cutaneous anthrax	off-label use	84980006	DOID:7426
Gastrointestinal anthrax	off-label use	111798006	DOID:13386
Pulmonary tuberculosis	off-label use	154283005	DOID:2957
Diverticulitis of gastrointestinal tract	off-label use	271366000
Ventilator-acquired pneumonia	off-label use	429271009
Diabetic Foot Infection	off-label use
Prevention of Meningococcal Meningitis	off-label use
Hallucinations	contraindication	7011001
Achilles tendinitis	contraindication	11654001
Agranulocytosis	contraindication	17182001	DOID:12987
Lowered convulsive threshold	contraindication	19260006
Torsades de pointes	contraindication	31722008
Transplantation of heart	contraindication	32413006
Dehydration	contraindication	34095006
Tendinitis	contraindication	34840004	DOID:971
Hypokalemia	contraindication	43339004
Bradycardia	contraindication	48867003
Hepatic failure	contraindication	59927004
Transplant of kidney	contraindication	70536003
Diabetes mellitus	contraindication	73211009	DOID:9351
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Transplant of lung	contraindication	88039007
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Prolonged QT interval	contraindication	111975006
Pancytopenia	contraindication	127034005	DOID:12450
Superimposed infection	contraindication	193198003
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Drug-induced hepatitis	contraindication	235876009
Rhabdomyolysis	contraindication	240131006
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Peripheral nerve disease	contraindication	302226006
Viral ear infection	contraindication	312137007
Pseudomembranous enterocolitis	contraindication	397683000
Myocardial ischemia	contraindication	414795007	DOID:3393
Traumatic rupture of tendon	contraindication	415749005
Congenital long QT syndrome	contraindication	442917000
Severe Cerebral Arteriosclerosis	contraindication
Tremors	contraindication
Shoulder Tendonitis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.12	acidic
pKa2	8.29	Basic
pKa3	1.12	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	4.54	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		IC50	4.41	WOMBAT-PK
Histamine H3 receptor	GPCR	Q9Y5N1	HRH3_HUMAN		IC50	4.55	WOMBAT-PK
Gamma-aminobutyric acid receptor subunit alpha-2	Ion channel	P47869	GBRA2_HUMAN		IC50	4.23	WOMBAT-PK
DNA gyrase subunit A	Enzyme		GYRA_ECOLI	INHIBITOR	IC50	5.28	WOMBAT-PK	CHEMBL
DNA gyrase subunit B	Enzyme		GYRB_ECO57				WOMBAT-PK
Gag-Pro-Pol polyprotein	Polyprotein		POL_HTL1A		IC50	4.82	WOMBAT-PK
GABA-A receptor; anion channel	Ion channel		GBRP_RAT GBRB1_RAT GBRD_RAT GBRG2_RAT GBRA5_RAT GBRA3_RAT GBRG1_RAT GBRA2_RAT GBRA4_RAT GBRG3_RAT GBRA6_RAT GBRA1_RAT GBRB3_RAT GBRB2_RAT Q91ZM7_RAT GBRE_RAT		IC50	4.96	CHEMBL
CAAX prenyl protease 1	Enzyme		STE24_YEAST		AC50	5.71	CHEMBL
Trypsin	Enzyme		TRYP_PIG		AC50	5.03	CHEMBL

External reference:

ID	Source
4019567	VUID
N0000147667	NUI
D00453	KEGG_DRUG
4019567	VANDF
CHEBI:7731	CHEBI
XED	PDB_CHEM_ID
CHEMBL4	ChEMBL_ID
10918	IUPHAR_LIGAND_ID
5322	INN_ID
118120-51-7	SECONDARY_CAS_RN
DB01165	DRUGBANK_ID
A4P49JAZ9H	UNII
7623	RXNORM
47400	MMSL
5197	MMSL
d00114	MMSL
003563	NDDF
004136	NDDF
387551000	SNOMEDCT_US
441553007	SNOMEDCT_US
96086002	SNOMEDCT_US
C0028902	UMLSCUI
D015242	MESH_DESCRIPTOR_UI
4583	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	0404-7189	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	24 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	0517-0760	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	22 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	0517-0761	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	22 sections
OCUFLOX	HUMAN PRESCRIPTION DRUG LABEL	1	11980-779	SOLUTION/ DROPS	3 mg	OPHTHALMIC	NDA	22 sections
OCUFLOX	HUMAN PRESCRIPTION DRUG LABEL	1	11980-779	SOLUTION/ DROPS	3 mg	OPHTHALMIC	NDA	22 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	13985-602	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	25 sections
OFLOXACIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-175	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	10 sections
OFLOXACIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-931	SOLUTION/ DROPS	3 mg	AURICULAR (OTIC)	ANDA	11 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-713	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	23 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-713	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	23 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-439	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	19 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-881	SOLUTION/ DROPS	3 mg	AURICULAR (OTIC)	ANDA	23 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	24208-410	SOLUTION	3 mg	AURICULAR (OTIC)	ANDA	18 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	24208-410	SOLUTION	3 mg	AURICULAR (OTIC)	ANDA	18 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	24208-434	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	20 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	24208-434	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	20 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	33261-737	SOLUTION	3 mg	AURICULAR (OTIC)	ANDA	18 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-257	SOLUTION	3 mg	AURICULAR (OTIC)	ANDA	18 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0891	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	22 sections
Ofloxacin Otic	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1090	SOLUTION	3 mg	AURICULAR (OTIC)	ANDA	20 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1346	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	22 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1346	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	22 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1744	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	19 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3836	SOLUTION/ DROPS	3 mg	AURICULAR (OTIC)	ANDA	23 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5186	SOLUTION	3 mg	OPHTHALMIC	ANDA	21 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5186	SOLUTION	3 mg	OPHTHALMIC	ANDA	21 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5186	SOLUTION	3 mg	OPHTHALMIC	ANDA	21 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5209	SOLUTION	3 mg	OPHTHALMIC	ANDA	21 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5210	SOLUTION	3 mg	OPHTHALMIC	ANDA	21 sections
Ofloxacin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5425	SOLUTION	3 mg	OPHTHALMIC	ANDA	13 sections